| abstract |
The present disclosure provides liquid formulations suitable for group B adenoviruses and their use in the treatment, especially in the treatment of cancer, which formulations a) Group B adenovirus, e.g., replication competent group B adenovirus, b) 15-25% v/v glycerol, for example 16, 17, 18, 19, 20, 21% v/v glycerol; And c) 0.1 to 1.5% v/v ethanol, for example 0.2 to 1%, eg 1% v/v ethanol; And d) a buffer, and e) optionally including amino acids, The pH of the formulation is in the range of 8.0 to 9.6. |